Baclofen for binge eating: An open-label trial

Allegra I. Broft; Alexia Spanos; Rebecca L. Corwin; Laurel Mayer; Joanna Steinglass; Michael J. Devlin; Evelyn Attia; B. Timothy Walsh

doi:10.1002/eat.20434

Baclofen for binge eating: An open-label trial

Allegra I. Broft, Alexia Spanos, Rebecca L. Corwin, Laurel Mayer, Joanna Steinglass, Michael J. Devlin, Evelyn Attia, B. Timothy Walsh

Nutritional Sciences

Research output: Contribution to journal › Article › peer-review

61 Scopus citations

Abstract

Objective: Baclofen is a GABA-B agonist that may be useful in the treatment of substance use disorders, and also reduces 'binge-like' eating in rodents. We hypothesized that baclofen might be effective in reducing binge eating episodes in binge eating disorder (BED) and bulimia nervosa (BN). Method: Seven women with BED (n = 4) or BN (n = 3) took baclofen (60 mg/day) for 10 weeks. Results: Six out of seven patients completed the full 10-week trial. Five out of seven participants (3 BED; 2 BN) demonstrated 50% or greater reduction of frequency of binge eating from beginning to end of the study. Three out of seven participants (2 BED; 1 BN) were free of binge eating at study end. Four out of seven participants elected to continue baclofen at study end. Baclofen was well tolerated by the participants. Conclusion: In this open-label trial, baclofen was associated with decreased binge eating frequency in patients with BED and BN.

Original language	English (US)
Pages (from-to)	687-691
Number of pages	5
Journal	International Journal of Eating Disorders
Volume	40
Issue number	8
DOIs	https://doi.org/10.1002/eat.20434
State	Published - Dec 2007

All Science Journal Classification (ASJC) codes

Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/eat.20434

Cite this

@article{087f4aa8fc3d4e388c680016f57ced3c,

title = "Baclofen for binge eating: An open-label trial",

abstract = "Objective: Baclofen is a GABA-B agonist that may be useful in the treatment of substance use disorders, and also reduces 'binge-like' eating in rodents. We hypothesized that baclofen might be effective in reducing binge eating episodes in binge eating disorder (BED) and bulimia nervosa (BN). Method: Seven women with BED (n = 4) or BN (n = 3) took baclofen (60 mg/day) for 10 weeks. Results: Six out of seven patients completed the full 10-week trial. Five out of seven participants (3 BED; 2 BN) demonstrated 50% or greater reduction of frequency of binge eating from beginning to end of the study. Three out of seven participants (2 BED; 1 BN) were free of binge eating at study end. Four out of seven participants elected to continue baclofen at study end. Baclofen was well tolerated by the participants. Conclusion: In this open-label trial, baclofen was associated with decreased binge eating frequency in patients with BED and BN.",

author = "Broft, {Allegra I.} and Alexia Spanos and Corwin, {Rebecca L.} and Laurel Mayer and Joanna Steinglass and Devlin, {Michael J.} and Evelyn Attia and Walsh, {B. Timothy}",

year = "2007",

month = dec,

doi = "10.1002/eat.20434",

language = "English (US)",

volume = "40",

pages = "687--691",

journal = "International Journal of Eating Disorders",

issn = "0276-3478",

publisher = "John Wiley and Sons Inc.",

number = "8",

}

TY - JOUR

T1 - Baclofen for binge eating

T2 - An open-label trial

AU - Broft, Allegra I.

AU - Spanos, Alexia

AU - Corwin, Rebecca L.

AU - Mayer, Laurel

AU - Steinglass, Joanna

AU - Devlin, Michael J.

AU - Attia, Evelyn

AU - Walsh, B. Timothy

PY - 2007/12

Y1 - 2007/12

N2 - Objective: Baclofen is a GABA-B agonist that may be useful in the treatment of substance use disorders, and also reduces 'binge-like' eating in rodents. We hypothesized that baclofen might be effective in reducing binge eating episodes in binge eating disorder (BED) and bulimia nervosa (BN). Method: Seven women with BED (n = 4) or BN (n = 3) took baclofen (60 mg/day) for 10 weeks. Results: Six out of seven patients completed the full 10-week trial. Five out of seven participants (3 BED; 2 BN) demonstrated 50% or greater reduction of frequency of binge eating from beginning to end of the study. Three out of seven participants (2 BED; 1 BN) were free of binge eating at study end. Four out of seven participants elected to continue baclofen at study end. Baclofen was well tolerated by the participants. Conclusion: In this open-label trial, baclofen was associated with decreased binge eating frequency in patients with BED and BN.

AB - Objective: Baclofen is a GABA-B agonist that may be useful in the treatment of substance use disorders, and also reduces 'binge-like' eating in rodents. We hypothesized that baclofen might be effective in reducing binge eating episodes in binge eating disorder (BED) and bulimia nervosa (BN). Method: Seven women with BED (n = 4) or BN (n = 3) took baclofen (60 mg/day) for 10 weeks. Results: Six out of seven patients completed the full 10-week trial. Five out of seven participants (3 BED; 2 BN) demonstrated 50% or greater reduction of frequency of binge eating from beginning to end of the study. Three out of seven participants (2 BED; 1 BN) were free of binge eating at study end. Four out of seven participants elected to continue baclofen at study end. Baclofen was well tolerated by the participants. Conclusion: In this open-label trial, baclofen was associated with decreased binge eating frequency in patients with BED and BN.

UR - http://www.scopus.com/inward/record.url?scp=36148971274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36148971274&partnerID=8YFLogxK

U2 - 10.1002/eat.20434

DO - 10.1002/eat.20434

M3 - Article

C2 - 17647277

AN - SCOPUS:36148971274

SN - 0276-3478

VL - 40

SP - 687

EP - 691

JO - International Journal of Eating Disorders

JF - International Journal of Eating Disorders

IS - 8

ER -

Baclofen for binge eating: An open-label trial

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this